1. Interleukin-37 Protects Stem Cell-Based Cartilage Formation in an Inflammatory Osteoarthritis-Like Microenvironment.
- Author
-
van Geffen EW, van Caam APM, Vitters EL, van Beuningen HM, van de Loo FA, van Lent PLEM, Koenders MI, and van der Kraan PM
- Subjects
- Cartilage metabolism, Cartilage pathology, Collagen metabolism, Culture Media, Conditioned pharmacology, Gene Expression Regulation drug effects, Humans, Inflammation genetics, Inflammation Mediators metabolism, Interleukin-1beta metabolism, Mesenchymal Stem Cells drug effects, Osteoarthritis genetics, Proteolysis drug effects, Cellular Microenvironment drug effects, Cellular Microenvironment genetics, Chondrogenesis drug effects, Chondrogenesis genetics, Cytoprotection, Inflammation pathology, Interleukin-1 metabolism, Mesenchymal Stem Cells metabolism, Osteoarthritis pathology
- Abstract
Impact Statement: Catabolic factors present in a damaged joint inhibit chondrogenic differentiation of mesenchymal stem cells, thereby reducing the chance for successful cartilage formation. By improving stem cell-based cartilage repair with interleukin-37 (IL37), we might be able to inhibit the worsening progression of focal cartilage defects and prevent further development of joint diseases such as osteoarthritis. This will avoid chronic pain and impaired joint mobility for patients and reduce costs for society.
- Published
- 2019
- Full Text
- View/download PDF